Moberg Pharma’s nomination committee appointed
STOCKHOLM, October 22[nd], 2021 – In accordance with the resolution of the Annual General Meeting on May 18[th], 2021, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee. As not all of the company’s three largest shareholders or group of shareholders have wished to appoint such representative, the fourth largest shareholder/group of shareholders have been invited to appoint one representative and so on until the Nomination Committee now comprises of four members, in accordance with the resolution of the Annual General Meeting on May 18[th], 2021.
Moberg Pharma’s Nomination Committee ahead of the Annual General Meeting for the fiscal year January – December 2021 comprises:
- Peter Wolpert, Chairman of the Board
- Gillis Cullin, appointed by Östersjöstiftelsen
- Anders Lundmark
- Martin Öhrn
Together, the Nomination Committee represents 13.6 percent of the shares in Moberg Pharma as of September 30th, 2021.
The Nomination Committee shall submit proposals for the fiscal year January – December 2021 by the Annual General Meeting pertaining to the election of Chairman of the Board, fees and composition of the Board, auditors’ fees and the election of auditors.
The 2021 Annual General Meeting for the fiscal year January – December 2021 will be held in Stockholm on May 16th. In regard to the ongoing COVID-19 pandemic Moberg Pharma will continue to closely monitor the Public Health Agency of Sweden´s recommendations. Should Moberg Pharma’s AGM be impacted in terms of attending the AGM in person, the company will inform its shareholders.
Shareholders wishing to submit proposals to Moberg Pharma’s Nomination Committee can do so by e-mail to info@mobergpharma.se by March 28th, 2022.
About this information
The information was submitted for publication, through the agency of the contact person set out below, at 8.30 a.m. CET on October 22nd, 2021.
For additional information, please contact:
Anna Ljung, CEO, Phone: +46 8 522 307 01, e-mail: anna.ljung@mobergpharma.se
About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company’s main asset, MOB-015, is a novel topical treatment for onychomycosis. Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in Europe and Japan, among others, and the company's intention is to submit a registration application during the second half of 2021 in Europe. Moberg Pharma is headquartered in Stockholm and the company’s shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB).